Androgen-deprivation therapy may double the risk of Alzheimer's disease, warns study

Androgen-deprivation therapy may double the risk of Alzheimer's disease, warns s

In a latest discovery, Stanford researchers have found that a common treatment for prostate cancer patients nearly makes twice the risk of being diagnosed with Alzheimer’s disease in just a few days following the treatment. A recent study has indicated that prostate cancer patients on androgen deprivation therapy (ADT) could be more vulnerable of developing dementia. The therapy is a treatment that decreases the levels of male hormones.

After lung cancer, prostate cancer is the largest cancer killer in men. Particularly, they looked for 5 associations with medical conditions like tuberculosis and allergies that are probably not linked to testosterone levels.

Men, who had undergone treatment with ADT for longer than a year showed 2.12 increased risk of Alzheimer’s disease, which was more than twice the risk in comparison to the ones who did not get ADT.

Clinicians always had an idea about a likely association between the hormonal therapy and Alzheimer’s. They added, “This study demonstrates the utility of novel methods to analyze electronic medical record data to generate practice-based evidence”.

Dr. Stuart Holden, medical director of the Prostate Cancer Foundation, said that such kinds of studies were significant as they give rise to queries but they don’t provide you answers. The foundation is a Santa Monica charity that collects funds for research related to prostate cancer research. Stanford University School of Medicine and the University Of Pennsylvania Perelman School Of Medicine conducted the study.

nouvelles generales: 
Share Share